Bernard-Soulier syndrome Medical Services in China

Bernard-Soulier syndrome (BSS) is a rare, inherited bleeding disorder caused by defects in the platelet glycoprotein Ib-IX-V complex — a critical receptor for von Willebrand factor (VWF) that mediates platelet adhesion to damaged vascular subendothelium. This autosomal recessive condition results in thrombocytopenia (low platelet count), abnormally large platelets (macrothrombocytes), and impaired platelet function, leading to prolonged bleeding time despite normal coagulation factor levels. Pathogenically, mutations in any of three genes — GP1BA, GP1BB, or GP9 — disrupt assembly or surface expression of the GPIb-IX-V complex, compromising the initial tethering step of hemostasis. As a consequence, patients exhibit mucocutaneous bleeding manifestations including easy bruising, epistaxis, gingival bleeding, menorrhagia, and prolonged bleeding after minor trauma or surgery. Severe cases may involve gastrointestinal or postpartum hemorrhage, though spontaneous intracranial or visceral bleeding is uncommon. Epidemiologically, BSS is extremely rare, with an estimated prevalence of 1 in 1 million individuals worldwide; fewer than 200 well-documented cases have been reported in the literature. It affects males and females equally and shows no ethnic predilection, though consanguinity significantly increases risk due to its autosomal recessive inheritance pattern. Risk factors include parental consanguinity, family history of unexplained bleeding or thrombocytopenia, and recurrent childhood hemorrhagic episodes misdiagnosed as immune thrombocytopenia (ITP). Quality of life impact is substantial: patients often experience anxiety around injury or invasive procedures, limitations in physical activity and sports participation, school or work absenteeism due to bleeding episodes or medical appointments, and psychosocial burden related to chronic disease management and reproductive concerns (e.g., menorrhagia, pregnancy-related hemorrhage risk). While not life-threatening in most cases with appropriate care, untreated or mismanaged BSS can lead to severe anemia, transfusion dependence, iron deficiency, and rare but catastrophic hemorrhage. Lifelong monitoring by a hematologist is essential, and patient education on bleeding avoidance, emergency protocols, and genetic counseling is integral to comprehensive care.

Bernard-Soulier syndrome (BSS) is a rare, autosomal recessive inherited bleeding disorder caused by defects in the GPIa/IIa (GPIa-2) complex—specifically, mutations in the GP1BA, GP1BB, or GP9 genes—resulting in deficient or dysfunctional platelet glycoprotein Ib-IX-V receptor. This receptor is essential for platelet adhesion to von Willebrand factor (VWF) at sites of vascular injury, leading to impaired primary hemostasis. Patients present with mucocutaneous bleeding (e.g., epistaxis, gingival bleeding, menorrhagia), prolonged bleeding time, thrombocytopenia, and abnormally large platelets (macrothrombocytes) on peripheral blood smear. Diagnosis relies on flow cytometry demonstrating reduced or absent CD42a (GPIa) and/or CD42b (GPIbα) expression, alongside genetic confirmation. Management is multidisciplinary and tailored to bleeding severity, surgical risk, and patient-specific factors.

Conservative treatment forms the cornerstone of long-term BSS management and emphasizes bleeding prevention and prompt non-invasive intervention. Patients must avoid antiplatelet agents (e.g., aspirin, NSAIDs, clopidogrel), anticoagulants unless absolutely indicated, and intramuscular injections. Comprehensive dental care—including prophylactic scaling, fluoride application, and early caries management—is critical to prevent gingival hemorrhage. Menstruating individuals benefit from hormonal therapy (e.g., combined oral contraceptives or levonorgestrel-releasing intrauterine systems) to reduce menstrual blood loss. Iron supplementation is routinely prescribed for chronic iron-deficiency anemia secondary to recurrent bleeding. Education on recognizing early signs of hemorrhage (e.g., prolonged oozing after minor trauma, petechiae, hematuria) and accessing emergency care is integral. Regular hematologic monitoring—including complete blood count, platelet count, and bleeding time assessment when clinically indicated—is recommended every 6–12 months in stable patients.

Pharmacologic interventions are limited due to the intrinsic platelet defect; however, several agents play adjunctive roles. Desmopressin (DDAVP) may transiently improve hemostasis in some BSS patients by promoting endothelial release of VWF and enhancing platelet–endothelium interaction, though response is variable and often suboptimal compared to other platelet disorders. Antifibrinolytics—particularly tranexamic acid—are highly effective for mucosal bleeding (e.g., epistaxis, dental procedures, menorrhagia) and are considered first-line medical therapy for acute or prophylactic use. Tranexamic acid inhibits plasminogen activation, thereby stabilizing clots formed despite defective platelet adhesion. It is administered orally (1–1.5 g three times daily) or intravenously (10 mg/kg bolus followed by 1 mg/kg/h infusion) perioperatively or during active bleeding. Recombinant activated factor VII (rFVIIa) has demonstrated efficacy in refractory bleeding episodes and major surgery, acting independently of platelet GPIb-IX-V by directly activating thrombin generation on tissue factor-expressing cells. However, its use is reserved for life-threatening hemorrhage or high-risk procedures due to cost, thrombotic risk, and lack of long-term safety data in BSS.

Surgical treatment is rarely curative but may be necessary in specific contexts. Splenectomy is contraindicated in BSS—not only because it fails to correct the underlying platelet defect but also because it increases the risk of overwhelming post-splenectomy infection (OPSI) and thrombosis without improving platelet counts or function. Hematopoietic stem cell transplantation (HSCT) remains the only potentially curative modality, but it is reserved for severe, transfusion-dependent cases with matched sibling donors due to substantial morbidity, mortality, and graft-versus-host disease risk. In China, HSCT protocols have evolved with improved HLA-typing accuracy, reduced-intensity conditioning regimens, and enhanced supportive care, yielding 5-year overall survival rates exceeding 85% in pediatric BSS patients undergoing matched sibling donor transplants. Gene therapy remains investigational, with preclinical studies targeting GP1BA correction in autologous CD34+ cells showing promising in vitro platelet functional restoration.

Treatment advantages in China include centralized expertise through national bleeding disorder centers affiliated with top-tier hospitals (e.g., Peking Union Medical College Hospital, Shanghai Ruijin Hospital), where multidisciplinary teams integrate hematology, transfusion medicine, obstetrics, dentistry, and genetics. China’s National Hemophilia Treatment Network ensures standardized diagnostic algorithms, including rapid-access flow cytometry and next-generation sequencing panels for GP1BA/GP1BB/GP9 analysis. The domestic production of high-purity tranexamic acid and rFVIIa (e.g., NovoSeven® biosimilars approved by the NMPA) significantly reduces treatment costs—up to 40% lower than imported equivalents—enhancing accessibility. Moreover, China’s robust blood bank infrastructure supports timely access to HLA-matched platelet transfusions, which remain the mainstay for perioperative hemostasis and life-threatening bleeding. Platelet transfusions, while effective acutely, require careful management to mitigate alloimmunization; Chinese centers employ extended HLA and HPA typing and implement platelet refractoriness protocols using crossmatch-compatible units.

Recovery and long-term prognosis hinge on proactive, individualized care. Patients should maintain a hemoglobin level >11 g/dL and ferritin >50 ng/mL to support erythropoiesis and minimize fatigue. Physical activity should be encouraged but modified to avoid contact sports and high-impact trauma; swimming and cycling are preferred. Vaccination adherence—including pneumococcal, meningococcal, and Haemophilus influenzae type b vaccines—is mandatory, especially for splenectomized or immunosuppressed individuals. Psychological support is vital: chronic bleeding disorders correlate with elevated anxiety and depression prevalence, and Chinese tertiary centers increasingly embed clinical psychologists within hemophilia/BSS clinics. Women of childbearing age require preconception counseling regarding inheritance risk (25% recurrence with consanguineous partners), fetal genotyping options (CVS/amniocentesis), and peripartum hemostatic planning—including neuraxial anesthesia avoidance and scheduled cesarean delivery with tranexamic acid and platelet coverage. With comprehensive care, most BSS patients achieve near-normal life expectancy and quality of life. Mortality remains primarily associated with intracranial hemorrhage, uncontrolled postpartum bleeding, or complications of invasive procedures—underscoring the necessity of coordinated, protocol-driven management across the continuum of care.